Advancing adoptive cellular immunotherapy via Notch-based ex vivo T cell development platforms.

Area of Science:

• Immunology
• Cell Biology
• Oncology

Background:

• T cell-based immunotherapies show promise for cancer treatment due to targeted and durable effects.
• Notch signaling is crucial for T cell development from various stem cell sources.
• Existing platforms offer flexibility in generating T cell progenitors or mature T cells.

Purpose of the Study:

• To review Notch signaling platforms for ex vivo T cell generation.
• To highlight advancements in Notch-based T cell immunotherapy.
• To discuss the potential of these platforms for clinical applications.

Main Methods:

• Utilizing hematopoietic stem and progenitor cells from diverse sources.
• Employing Notch signaling pathways for T cell lineage commitment and differentiation.
• Engineering T cells to express chimeric antigen receptors (CARs).
• Developing stromal cell-dependent and stromal cell-free systems.

Main Results:

• Notch platforms can produce T cell progenitors for off-the-shelf immunotherapy.
• Engineered T cells exhibit potent, tumor-specific activity.
• Stromal cell-free systems offer clinical scalability.
• Enhancements like VCAM-1 improve T cell production efficiency.

Conclusions:

• Notch signaling platforms are pivotal in advancing adoptive T cell immunotherapy.
• These platforms facilitate the development of novel cancer treatments.
• Further optimization of Notch-based systems holds significant therapeutic potential.